Ongoing clinical trials of multi-targeting TKIs therapy in UC
Drugs | Targets | Combination | Conditions | Phase | NCT |
---|---|---|---|---|---|
Anlotinib | VEGFR, FGFR, PDGFR, c-kit | Platinum/Gemcitabine | UC | II | NCT05030077 |
Axitinib | VEGFR2, PDGFRβ, c-kit, | PF-07265807 | Adv/Met solid tumors | I | NCT04458259 |
Cabozantinib | AXL, HGFR, VEGFR | Durvalumab | UC | II | NCT03824691 |
Cabozantinib | AXL, HGFR, VEGFR | Atezolizumab | UC | II | NCT04289779 |
Cabozantinib | AXL, HGFR, VEGFR | Pembrolizumab | Met UC | II | NCT03534804 |
Cabozantinib | AXL, HGFR, VEGFR | Atezolizumab | UC | I/II | NCT03170960 |
Cabozantinib | AXL, HGFR, VEGFR | Ipilimumab/Nivolumab | UC | II | NCT03866382 |
Cabozantinib | AXL, HGFR, VEGFR | Avelumab | Adv /Met UC | III | NCT05092958 |
Cabozantinib | AXL, HGFR, VEGFR | Nivolumab/Nivolumab + Ipilimumab | Met/Adv UC | I | NCT02496208 |
Cabozantinib | AXL, HGFR, VEGFR | Enfortumab Vedotin | Met/Adv UC | I | NCT04878029 |
Cabozantinib | AXL, HGFR, VEGFR | Nivolumab | Bladder Melanoma | II | NCT05111574 |
Cabozantinib | AXL, HGFR, VEGFR | Nivolumab | Rec UC | I | NCT04514484 |
Famitinib | c-kit, VEGFR2, PDGFRβ | Camrelizumab | UC | II | NCT03827837 |
VEGFR: vascular endothelial growth factor receptor; FGFR: fibroblast growth factor receptor; PDGFR: platelet-derived growth factor receptor; HGFR: hepatocyte growth factor receptor; TKIs: tyrosine kinase inhibitors; UC: urothelial carcinoma; Adv: advanced; Met: metastatic; Rec: recurrent; NCT: national clinical trial
SS, LZ, and KL contributed equally to: Writing—original draft, Writing—review & editing. ML, JZ, DJ, DW, ZS, and PX: Investigation, Writing—review & editing. JY and ZZ: Conceptualization, Writing—review & editing, Supervision. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
This study was supported by the Shaanxi Province Key Industry Chain Project [2022ZDLSF05-14]. The funder played no role in the study design, data collection and analysis, decision to publish, or in the preparation of the manuscript.
© The Author(s) 2024.